Abstract:Objective: To investigate the effect of etomidate on PI3K/AKT pathway and apoptosis of non-small cell lung cancer A549 cell. Methods: A549 cell group, 5-fluorouracil group, etomidate low-dose group and high-dose group were set up. 5-fluorouracil group, etomidate low-dose group and high-dose group were added 5-fluorouracil group and etomidate at different concentrations, and the final concentration was 100.0ug/mL, 100.0ug/mL and 200.0ug/mL for 72 hours. Cell proliferation level was assessed by cell counting kit-8, apoptotic level was measured by flow cytometry, cell invasiveness was measured by Transwell chamber, p-PI3K, p-AKT mRNA and protein levels were measured by RT-PCR and WEST-BLOT. Results: Compared with A549 cell group, the OD value, survival rate, number of perforation, p-PI3K, p-AKT gene and protein were significantly decreased in 5-fluorouracil group, low-dose and high-dose etomidate group(P<0.05), apoptotic rate were significantly increased(P<0.05). And with the increase of etomidate dosage, the OD value, survival rate, number of perforation, p-PI3K, p-AKT gene and protein were gradually decreased (P<0.05), apoptotic rate were gradually increased (P<0.05). Compared with 5-fluorouracil group, the OD value, survival rate, number of perforations, p-PI3K, p-AKT mRNA and protein in low-dose etomidate group were significantly increased(P<0.05), and apoptotic rate were significantly decreased (P<0.05); while the OD value, survival rate, number of perforation, p-PI3K, p-AKT mRNA and protein in high-dose etomidate group were significantly decreased(P<0.05), and apoptotic rate were significantly increased(P<0.05). Conclusion: Etomidate can inhibit the proliferation and invasion of lung cancer A549 cells and promote the apoptosis of lung cancer A549 cells. Its mechanism is related to the inhibition of PI3K/AKT pathway activation and transmission by reducing the levels of p-PI3K, p-AKT mRNA and protein phosphorylation by etomidate.
杜佳楠, 戴勤学, 容凤娇, 徐夏. 依托咪酯对PI3K/AKT通路及非小细胞肺癌A549细胞凋亡的影响[J]. 河北医学, 2020, 26(7): 1066-1071.
DU Jia'nan, et al. Effects of Etomidate on PI3K / AKT Pathway and Apoptosis of Non-small Cell Lung Cancer A549 Cells. HeBei Med, 2020, 26(7): 1066-1071.
[1] 辛雯艳,黄磊,闫贻忠.2005-2013年中国肿瘤登记地区肺癌流行和疾病负担时间趋势分析[J].中华肿瘤防治杂志,2019,26(15):1059~1065. [2] 崔晓霞,宋鹏,张力.小细胞肺癌诊疗新进展[J].中国肺癌杂志,2019,22(6):355~362. [3] 王春,朱昌娥,章赛吉,等.依托咪酯用量对左向右分流先天性心脏病患儿血流动力学及脑电双频指数的影响[J].上海交通大学学报(医学版),2017,37(12):1650~1652. [4] 康建勋,国世刚,李经利.地佐辛联合依托咪酯用于肝癌射频消融术的效果[J].中国医药导报,2017,14(9):182~185. [5] 王雷,牛志强,郑孟良,等.右美托咪定复合依托咪酯麻醉对直肠癌术后医院感染患者免疫功能及炎性因子的影响分析[J].中华医院感染学杂志,2017,27(21):4949~4952. [6] Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials[J]. Pharmacol Ther, 2017, 175(1):91~106. [7] 林安琪,陈雨晴,张小利,等.非小细胞肺癌免疫治疗“超进展”[J].肿瘤,2019,39(8):680~690. [8] Komatsu R, You J, Rajan S, et al. Steroid administration after anaesthetic induction with etomidate does not reduce in-hospital mortality or cardiovascular morbidity after non-cardiac surgery[J]. Br Anaesth, 2018, 120(3):501~508. [9] Gupta P, Gupta M. Comparison of different doses of intravenous lignocaine on etomidate-induced myoclonus: a prospective randomised and placebo-controlled study[J]. Indian Anaesth, 2018, 62(2):121~126. [10] Katz J, Greenberg S. Etomidate Is NOT a First-Line Induction Agent in Critically Ill Patients[J]. Crit Care Med, 2018, 46(9):1495~1496. [11] 朱敏,刘亚华,于婵娟.依托咪酯对垂体瘤细胞迁移能力影响的研究[J].中国临床药理学杂志,2018,34(11):1357~1360. [12] Diaz-Serrano A, Angulo B, Dominguez C, et al. Genomic profiling of HER2-positive gastric cancer: PI3K/Akt/mTOR pathway as predictor of outcomes in HER2-Positive advanced gastric cancer treated with trastuzumab[J]. Oncologist, 2018, 23(9):1092~1102. [13] Mazzon M, Castro C, Thaa B, et al. Alphavirus-induced hyperactivation of PI3K/AKT directs pro-viral metabolic changes[J]. Plos Pathogens, 2018, 14(1):e1006835. [14] Mao Y, Xi L, Li Q, et al. Combination of PI3K/Akt pathway inhibition and Plk1 depletion can enhance chemosensitivity to gemcitabine in pancreatic carcinoma[J]. Transl Oncol, 2018, 11(4):852~863. [15] Zhou R, Chen H, Chen J, et al. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway[J]. BMC Complement Altern Med, 2018, 18(1):83~94.